Samsara BioCapital LLC Sells 22,526 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Samsara BioCapital LLC decreased its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 50.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,526 shares of the company's stock after selling 22,526 shares during the quarter. Samsara BioCapital LLC's holdings in Janux Therapeutics were worth $1,023,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Summit Securities Group LLC bought a new position in Janux Therapeutics during the 2nd quarter worth $29,000. Amalgamated Bank increased its holdings in shares of Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company's stock worth $41,000 after purchasing an additional 368 shares during the period. Plato Investment Management Ltd acquired a new position in Janux Therapeutics in the 2nd quarter valued at $42,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock worth $87,000 after buying an additional 339 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Janux Therapeutics in the second quarter valued at approximately $151,000. Institutional investors own 75.39% of the company's stock.

Analyst Ratings Changes

JANX has been the subject of a number of research reports. BTIG Research increased their target price on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday. Scotiabank boosted their price objective on shares of Janux Therapeutics from $42.00 to $62.00 and gave the stock a "sector perform" rating in a research note on Wednesday. Leerink Partnrs raised shares of Janux Therapeutics to a "strong-buy" rating in a research report on Friday, November 22nd. Cantor Fitzgerald restated an "overweight" rating and issued a $100.00 price target on shares of Janux Therapeutics in a research report on Thursday, November 7th. Finally, Stifel Nicolaus upped their price target on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a "buy" rating in a research report on Tuesday. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $79.90.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX traded down $1.19 during mid-day trading on Thursday, reaching $65.65. 3,291,215 shares of the company's stock traded hands, compared to its average volume of 773,712. The business has a 50-day simple moving average of $50.21 and a 200 day simple moving average of $45.96. The stock has a market cap of $3.45 billion, a P/E ratio of -58.37 and a beta of 3.29. Janux Therapeutics, Inc. has a 1-year low of $7.79 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.18). The company had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Janux Therapeutics's quarterly revenue was down 82.6% on a year-over-year basis. Equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Transactions at Janux Therapeutics

In other news, CEO David Alan Campbell sold 15,000 shares of Janux Therapeutics stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $67.00, for a total transaction of $1,005,000.00. Following the sale, the chief executive officer now directly owns 242,054 shares in the company, valued at $16,217,618. The trade was a 5.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Andrew Hollman Meyer sold 50,000 shares of Janux Therapeutics stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the completion of the sale, the insider now directly owns 67,592 shares in the company, valued at approximately $3,106,528.32. This represents a 42.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 460,610 shares of company stock worth $21,583,666 in the last quarter. 29.40% of the stock is currently owned by corporate insiders.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.